List of Tables
    Table 1. Recurrent Glioblastoma Multiforme Treatment Market Size United States VS Global, CAGR (2017 VS 2022 VS 2028)
    Table 2. Recurrent Glioblastoma Multiforme Treatment Market Trends
    Table 3. Recurrent Glioblastoma Multiforme Treatment Market Drivers
    Table 4. Recurrent Glioblastoma Multiforme Treatment Market Challenges
    Table 5. Recurrent Glioblastoma Multiforme Treatment Market Restraints
    Table 6. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 7. United States Recurrent Glioblastoma Multiforme Treatment Market Size by Type: 2017 VS 2022 VS 2028 (US$ Million)
    Table 8. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 9. United States Recurrent Glioblastoma Multiforme Treatment Market Size by Application: 2017 VS 2022 VS 2028 (US$ Million)
    Table 10. Top Recurrent Glioblastoma Multiforme Treatment Companies in Global Market, Ranking by Revenue (2021)
    Table 11. Global Recurrent Glioblastoma Multiforme Treatment Revenue by Player, (US$ Million), 2017-2022
    Table 12. Global Recurrent Glioblastoma Multiforme Treatment Revenue Share by Player, 2017-2022
    Table 13. Global Recurrent Glioblastoma Multiforme Treatment Companies Market Concentration Ratio (CR5 and HHI)
    Table 14. Global Recurrent Glioblastoma Multiforme Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Recurrent Glioblastoma Multiforme Treatment as of 2021)
    Table 15. Top Players of Recurrent Glioblastoma Multiforme Treatment in Global Market, Headquarters and Area Served
    Table 16. Companies Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022) & (US$ Million) Type
    Table 17. Date of International Companies Enter into Recurrent Glioblastoma Multiforme Treatment Market
    Table 18. Companies Mergers & Acquisitions, Expansion Plans
    Table 19. Top Recurrent Glioblastoma Multiforme Treatment Players in United States Market, Ranking by Revenue (2021)
    Table 20. United States Recurrent Glioblastoma Multiforme Treatment Revenue by Players, (US$ Million), 2020, 2021 & 2022
    Table 21. United States Recurrent Glioblastoma Multiforme Treatment Revenue Share by Players, 2020, 2021 & 2022
    Table 22. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Region (US$ Million): 2017 VS 2022 VS 2028
    Table 23. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Region (2017-2022) & (US$ Million)
    Table 24. Global Recurrent Glioblastoma Multiforme Treatment Market Size Forecast by Region (2023-2028) & (US$ Million)
    Table 25. North America Recurrent Glioblastoma Multiforme Treatment Sales in Value by Country (2017-2028) & (US$ Million)
    Table 26. Asia Pacific Recurrent Glioblastoma Multiforme Treatment Sales in Value by Region (2017-2028) & (US$ Million)
    Table 27. Europe Recurrent Glioblastoma Multiforme Treatment Sales in Value by Country (2017-2028) & (US$ Million)
    Table 28. Latin Americaa Recurrent Glioblastoma Multiforme Treatment Sales in Value by Country (2017-2028) & (US$ Million)
    Table 29. Middle East and Africa Recurrent Glioblastoma Multiforme Treatment Sales in Value by Country (2017-2028) & (US$ Million)
    Table 30. Boehringer Ingelheim GmbH Company Details
    Table 31. Boehringer Ingelheim GmbH Business Overview
    Table 32. Boehringer Ingelheim GmbH Recurrent Glioblastoma Multiforme Treatment Product
    Table 33. Boehringer Ingelheim GmbH Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022) & (US$ Million)
    Table 34. Boehringer Ingelheim GmbH Recent Development
    Table 35. Boston Biomedical, Inc. Company Details
    Table 36. Boston Biomedical, Inc. Business Overview
    Table 37. Boston Biomedical, Inc. Recurrent Glioblastoma Multiforme Treatment Product
    Table 38. Boston Biomedical, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022) & (US$ Million)
    Table 39. Boston Biomedical, Inc. Recent Development
    Table 40. Bristol-Myers Squibb Company Company Details
    Table 41. Bristol-Myers Squibb Company Business Overview
    Table 42. Bristol-Myers Squibb Company Recurrent Glioblastoma Multiforme Treatment Product
    Table 43. Bristol-Myers Squibb Company Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022) & (US$ Million)
    Table 44. Bristol-Myers Squibb Company Recent Development
    Table 45. Cantex Pharmaceuticals, Inc. Company Details
    Table 46. Cantex Pharmaceuticals, Inc. Business Overview
    Table 47. Cantex Pharmaceuticals, Inc. Recurrent Glioblastoma Multiforme Treatment Product
    Table 48. Cantex Pharmaceuticals, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022) & (US$ Million)
    Table 49. Cantex Pharmaceuticals, Inc. Recent Development
    Table 50. Cavion LLC Company Details
    Table 51. Cavion LLC Business Overview
    Table 52. Cavion LLC Recurrent Glioblastoma Multiforme Treatment Product
    Table 53. Cavion LLC Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022) & (US$ Million)
    Table 54. Cavion LLC Recent Development
    Table 55. Celldex Therapeutics, Inc. Company Details
    Table 56. Celldex Therapeutics, Inc. Business Overview
    Table 57. Celldex Therapeutics, Inc. Recurrent Glioblastoma Multiforme Treatment Product
    Table 58. Celldex Therapeutics, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022) & (US$ Million)
    Table 59. Celldex Therapeutics, Inc. Recent Development
    Table 60. Coherus BioSciences, Inc. Company Details
    Table 61. Coherus BioSciences, Inc. Business Overview
    Table 62. Coherus BioSciences, Inc. Recurrent Glioblastoma Multiforme Treatment Product
    Table 63. Coherus BioSciences, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022) & (US$ Million)
    Table 64. Coherus BioSciences, Inc. Recent Development
    Table 65. Cortice Biosciences, Inc. Company Details
    Table 66. Cortice Biosciences, Inc. Business Overview
    Table 67. Cortice Biosciences, Inc. Recurrent Glioblastoma Multiforme Treatment Product
    Table 68. Cortice Biosciences, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022) & (US$ Million)
    Table 69. Cortice Biosciences, Inc. Recent Development
    Table 70. Eisai Company Details
    Table 71. Eisai Business Overview
    Table 72. Eisai Recurrent Glioblastoma Multiforme Treatment Product
    Table 73. Eisai Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022) & (US$ Million)
    Table 74. Eisai Recent Development
    Table 75. Eli Lilly and Company Company Details
    Table 76. Eli Lilly and Company Business Overview
    Table 77. Eli Lilly and Company Recurrent Glioblastoma Multiforme Treatment Product
    Table 78. Eli Lilly and Company Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022) & (US$ Million)
    Table 79. Eli Lilly and Company Recent Development
    Table 80. EnGeneIC Ltd Company Details
    Table 81. EnGeneIC Ltd Business Overview
    Table 82. EnGeneIC Ltd Recurrent Glioblastoma Multiforme Treatment Product
    Table 83. EnGeneIC Ltd Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022) & (US$ Million)
    Table 84. EnGeneIC Ltd Recent Development
    Table 85. ERC Belgium SA Company Details
    Table 86. ERC Belgium SA Business Overview
    Table 87. ERC Belgium SA Recurrent Glioblastoma Multiforme Treatment Product
    Table 88. ERC Belgium SA Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022) & (US$ Million)
    Table 89. ERC Belgium SA Recent Development
    Table 90. GenSpera, Inc. Company Details
    Table 91. GenSpera, Inc. Business Overview
    Table 92. GenSpera, Inc. Recurrent Glioblastoma Multiforme Treatment Product
    Table 93. GenSpera, Inc. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022) & (US$ Million)
    Table 94. GenSpera, Inc. Recent Development
    Table 95. Genzyme Corporation Company Details
    Table 96. Genzyme Corporation Business Overview
    Table 97. Genzyme Corporation Recurrent Glioblastoma Multiforme Treatment Product
    Table 98. Genzyme Corporation Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022) & (US$ Million)
    Table 99. Genzyme Corporation Recent Development
    Table 100. GW Pharmaceuticals Plc Company Details
    Table 101. GW Pharmaceuticals Plc Business Overview
    Table 102. GW Pharmaceuticals Plc Recurrent Glioblastoma Multiforme Treatment Product
    Table 103. GW Pharmaceuticals Plc Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022) & (US$ Million)
    Table 104. GW Pharmaceuticals Plc Recent Development
    Table 105. ImmunoCellular Therapeutics, Ltd. Company Details
    Table 106. ImmunoCellular Therapeutics, Ltd. Business Overview
    Table 107. ImmunoCellular Therapeutics, Ltd. Recurrent Glioblastoma Multiforme Treatment Product
    Table 108. ImmunoCellular Therapeutics, Ltd. Revenue in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022) & (US$ Million)
    Table 109. ImmunoCellular Therapeutics, Ltd. Recent Development
    Table 110. Research Programs/Design for This Report
    Table 111. Key Data Information from Secondary Sources
    Table 112. Key Data Information from Primary Sources
List of Figures
    Figure 1. Recurrent Glioblastoma Multiforme Treatment Product Picture
    Figure 2. Global Recurrent Glioblastoma Multiforme Treatment Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 3. Global Recurrent Glioblastoma Multiforme Treatment Market Size 2017-2028 (US$ Million)
    Figure 4. United States Recurrent Glioblastoma Multiforme Treatment Market Size, (US$ Million), 2017 VS 2022 VS 2028
    Figure 5. United States Recurrent Glioblastoma Multiforme Treatment Market Size 2017-2028 (US$ Million)
    Figure 6. United States Recurrent Glioblastoma Multiforme Treatment Market Share in Global 2017-2028
    Figure 7. Recurrent Glioblastoma Multiforme Treatment Report Years Considered
    Figure 8. Product Picture of AU-105
    Figure 9. Product Picture of Axitinib
    Figure 10. Product Picture of AXL-1717
    Figure 11. Product Picture of AZD-7451
    Figure 12. Product Picture of Others
    Figure 13. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Type in 2022 & 2028
    Figure 14. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2017-2028) & (US$ Million)
    Figure 15. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Type (2017-2028)
    Figure 16. United States Recurrent Glioblastoma Multiforme Treatment Market Share by Type in 2022 & 2028
    Figure 17. United States Recurrent Glioblastoma Multiforme Treatment Market Size by Type (2017-2028) & (US$ Million)
    Figure 18. United States Recurrent Glioblastoma Multiforme Treatment Market Share by Type (2017-2028)
    Figure 19. Product Picture of Hospital
    Figure 20. Product Picture of Clinic
    Figure 21. Product Picture of Others
    Figure 22. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Application in 2022 & 2028
    Figure 23. Global Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2017-2028) & (US$ Million)
    Figure 24. Global Recurrent Glioblastoma Multiforme Treatment Market Share by Application (2017-2028)
    Figure 25. United States Recurrent Glioblastoma Multiforme Treatment Market Share by Application in 2022 & 2028
    Figure 26. United States Recurrent Glioblastoma Multiforme Treatment Market Size by Application (2017-2028) & (US$ Million)
    Figure 27. United States Recurrent Glioblastoma Multiforme Treatment Market Share by Application (2017-2028)
    Figure 28. North America Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 29. U.S. Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 30. Canada Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 31. Europe Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 32. Germany Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 33. France Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 34. U.K. Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 35. Italy Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 36. Russia Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 37. Asia-Pacific Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 38. China Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 39. Japan Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 40. South Korea Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 41. India Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 42. Australia Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 43. Taiwan Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 44. Indonesia Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 45. Thailand Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 46. Malaysia Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 47. Philippines Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 48. Latin America Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 49. Mexico Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 50. Brazil Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 51. Argentina Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 52. Middle East & Africa Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate 2017-2028 (US$ Million)
    Figure 53. Turkey Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 54. Saudi Arabia Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 55. U.A.E Recurrent Glioblastoma Multiforme Treatment Market Size Growth Rate (2017-2028) & (US$ Million)
    Figure 56. Boehringer Ingelheim GmbH Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022)
    Figure 57. Boston Biomedical, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022)
    Figure 58. Bristol-Myers Squibb Company Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022)
    Figure 59. Cantex Pharmaceuticals, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022)
    Figure 60. Cavion LLC Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022)
    Figure 61. Celldex Therapeutics, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022)
    Figure 62. Coherus BioSciences, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022)
    Figure 63. Cortice Biosciences, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022)
    Figure 64. Eisai Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022)
    Figure 65. Eli Lilly and Company Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022)
    Figure 66. EnGeneIC Ltd Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022)
    Figure 67. ERC Belgium SA Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022)
    Figure 68. GenSpera, Inc. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022)
    Figure 69. Genzyme Corporation Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022)
    Figure 70. GW Pharmaceuticals Plc Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022)
    Figure 71. ImmunoCellular Therapeutics, Ltd. Revenue Growth Rate in Recurrent Glioblastoma Multiforme Treatment Business (2017-2022)
    Figure 72. Bottom-up and Top-down Approaches for This Report
    Figure 73. Data Triangulation
    Figure 74. Key Executives Interviewed